BioAge Labs, Inc. (BIOA): who owns it and who trades it
As of Nov 16, 2026, BIOA insiders reported 13 open-market sales worth $7.8M and no purchases in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Kristen Fortney (CEO), with $4.2M. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling BioAge Labs
From the latest filingsOverall: more buying than selling. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns BIOA
152 funds and institutions reported BIOA shares worth $932M at the end of Q2 2026, about 86% of the company. The largest holder is A16z Capital Management, L.L.C. with 7.3%.
Funds and institutions (13F) 86%Everyone else 14%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| A16z Capital Management, L.L.C. | 3.23M | 7.29% | $79.2M | No change |
| BlackRock, Inc. | 2.85M | 6.42% | $69.8M | +26% |
| Cormorant Asset Management, LP | 2.39M | 5.39% | $58.6M | -17% |
| Sofinnova Investments, Inc. | 2.29M | 5.17% | $56.2M | No change |
| Jupiter Topco LLC | 2.14M | 4.83% | $52.6M | – |
| Octagon Capital Advisors LP | 1.75M | 3.94% | $42.8M | No change |
| Ra Capital Management, L.P. | 1.67M | 3.77% | $41M | +1% |
| Mpm Bioimpact LLC | 1.67M | 3.76% | $40.9M | – |
| Vanguard Capital Management LLC | 1.54M | 3.48% | $37.8M | +14% |
| Polar Capital Holdings Plc | 1.07M | 2.42% | $26.3M | -5% |
| Braidwell LP | 1.03M | 2.33% | $25.3M | -14% |
| State Street Corp | 1.02M | 2.30% | $25M | +20% |
| Geode Capital Management, LLC | 1.00M | 2.26% | $24.6M | +34% |
| Sands Capital Alternatives, LLC | 786,353 | 1.77% | $19.3M | No change |
| Orbimed Advisors LLC | 752,153 | 1.69% | $18.4M | +6% |
| D. E. Shaw & Co., Inc. | 742,761 | 1.67% | $18.2M | +6% |
| Balyasny Asset Management L.P. | 702,858 | 1.58% | $17.2M | -47% |
| Pivotal bioVenture Partners Investment Advisor LLC | 653,374 | 1.47% | $16M | No change |
| Cosmic Management, LLC | 501,833 | 1.13% | $12.3M | No change |
| Stempoint Capital LP | 464,171 | 1.05% | $11.4M | -31% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, BIOA insiders reported $0 of open-market purchases and $7.8M of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | Shane Barton | Principal Accounting Off | Sale plan | 20,216 | $25.19 | $509K | Form 4 |
| Jun 29, 2026 | Shane Barton | Principal Accounting Off | Sale plan | 42,350 | $25.21 | $1.1M | Form 4 |
| Apr 1, 2026 | Paul D Rubin | Chief Medical Officer | Sale plan | 8,820 | $17.81 | $157K | Form 4 |
| Mar 2, 2026 | Paul D Rubin | Chief Medical Officer | Sale plan | 7,433 | $20.30 | $151K | Form 4 |
| Feb 2, 2026 | Paul D Rubin | Chief Medical Officer | Sale plan | 7,433 | $18.75 | $139K | Form 4 |
| Jan 13, 2026 | Dov A Md Goldstein | CFO | Sale plan | 4,440 | $19.45 | $86.4K | Form 4 |
| Jan 13, 2026 | Dov A Md Goldstein | CFO | Sale plan | 11,663 | $20.54 | $240K | Form 4 |
| Jan 13, 2026 | Dov A Md Goldstein | CFO | Sale plan | 1,923 | $21.08 | $40.5K | Form 4 |
| Jan 13, 2026 | Dov A Md Goldstein | CFO | Sale plan | 8,974 | $18.43 | $165K | Form 4 |
| Jan 13, 2026 | Kristen Fortney | CEO | Sale plan | 233,107 | $18.12 | $4.2M | Form 4 |
| Jan 2, 2026 | Paul D Rubin | Chief Medical Officer | Sale plan | 7,433 | $12.85 | $95.5K | Form 4 |
| Dec 9, 2025 | Paul D Rubin | Chief Medical Officer | Sale plan | 18,000 | $12.00 | $216K | Form 4 |
| Dec 4, 2025 | Paul D Rubin | Chief Medical Officer | Sale plan | 68,897 | $10.19 | $702K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Kristen Fortney | Chief Executive Officer, Director | – | $4.2M | Jan 13, 2026 |
| Shane Barton | Principal Accounting Officer | – | $1.6M | Jun 30, 2026 |
| Paul D Rubin | Chief Medical Officer | – | $1.5M | Apr 1, 2026 |
| Dov A Md Goldstein | Chief Financial Officer | – | $532K | Jan 13, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
BIOA short interest
Moderate short interest. 8.1% of BIOA shares are sold short: about 1 share in 12. Over the last 12 reports the number of shares short went up 118%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 3.73M BIOA shares were sold short, 8.1% of the shares outstanding, up 8.6% from the report before. At the average daily volume of 857,733 shares, buying them all back would take about 4.3 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 3.73M | 8.11% | +9% | 857,733 | 4.3 |
| Oct 15, 2026 | 3.43M | 7.48% | +5% | 932,308 | 3.7 |
| Sep 30, 2026 | 3.27M | 7.13% | +7% | 830,478 | 3.9 |
| Sep 15, 2026 | 3.07M | 6.70% | +13% | 506,919 | 6.1 |
| Aug 31, 2026 | 2.72M | 5.93% | +23% | 577,222 | 4.7 |
| Aug 14, 2026 | 2.22M | 4.83% | -14% | 1.16M | 1.9 |
| Jul 31, 2026 | 2.57M | 5.59% | +5% | 1.36M | 1.9 |
| Jul 15, 2026 | 2.45M | 5.52% | -35% | 540,360 | 4.5 |
| Jun 30, 2026 | 3.74M | 8.44% | +88% | 932,909 | 4.0 |
| Jun 15, 2026 | 1.99M | 4.49% | +11% | 383,084 | 5.2 |
| May 29, 2026 | 1.79M | 4.03% | +5% | 474,182 | 3.8 |
| May 15, 2026 | 1.71M | 3.85% | -9% | 372,464 | 4.6 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
BioAge Labs company events
BioAge Labs filed 10 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Oct 2, 2026AnnouncementBioAge Labs, Inc. recently announced that the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial evaluating once-daily oral BGE-102, an NLRP3 inhibitor, in adults with diabetic macular edema, and provided updates on the QUELL-DME Phase 2 trial design. Filing
- Aug 5, 2026ResultsReleased financial results. Filing
- Jun 12, 2026VoteReported shareholder vote results. Filing
- May 8, 2026ResultsReleased financial results. Filing
- Mar 24, 2026ResultsReleased financial results. Filing
- Jan 22, 2026AgreementBioAge Labs, Inc., a Delaware corporation entered into an underwriting agreement with Goldman Sachs & Co. LLC, Piper Sandler & Co. and Citigroup Global Markets Inc. as representatives of the underwriters named therein, pursuant to which the Company agreed to issue and sell 5,897,435 shares of its… Filing
- Jan 20, 2026AnnouncementThe Company announced indication expansion for oral NLRP3 inhibitor BGE-102. • Growing preclinical and clinical evidence points to central role of the inflammasome in multiple retinal diseases where inflammation is a key feature, including diabetic macular edema o In a preclinical model of DME… Filing
- Jan 12, 2026AnnouncementThe Company announced additional positive interim Phase 1 data for BGE-102, a novel brain-penetrant NLRP3 inhibitor, demonstrating potential for best-in-class hsCRP reduction in participants with elevated cardiovascular risk. • First BGE-102 multiple ascending dose cohort completed in obese… Filing
- Dec 4, 2025AnnouncementThe Company announced positive interim data from its ongoing Phase 1 single ascending dose (SAD) / multiple ascending dose (MAD) clinical trial evaluating BGE-102 a potent, structurally novel, orally available, brain-penetrant small molecule NLRP3 inhibitor being developed for treatment of patients… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
BioAge Labs financials
Famous investors that hold BIOA
3 of the 50 well-known investors we track reported holding BIOA in their latest 13F filing. The largest position is Israel Englander's, worth $4.5M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 636,546 | $4.5M | 0.0% | +186% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 626,661 | $4.4M | 0.0% | +278% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 41,538 | $295K | 0.0% | -47% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named BIOA in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Cormorant Asset Management, LP | 13G/A | 4.9% |
| Nov 16, 2026 | Cormorant Asset Management, LP | 13G/A | 4.9% |
Questions about BioAge Labs, Inc. (BIOA) stock
Who owns the most BIOA stock?
The largest reported owner of BioAge Labs, Inc. (BIOA) is A16z Capital Management, L.L.C., with 7.3% of the company. In total, 152 funds and institutions reported holding BIOA at the end of Q2 2026, together about 86% of the shares. See the largest owners.
Are BIOA insiders buying or selling?
In the last 12 months, BIOA insiders reported no open-market purchases and 13 sales worth $7.8M. The latest trade was on Jun 30, 2026. See every trade.
What is the short interest in BIOA?
As of Oct 30, 2026, 3.73M BIOA shares were sold short, 8.1% of the shares outstanding, up 8.6% from the report before. At the average daily volume of 857,733 shares, buying them all back would take about 4.3 trading days (days to cover). See the history.
Which famous investors hold BIOA?
3 of the 50 well-known investors we track reported BIOA in their latest 13F filing, including Israel Englander, Jim Simons, Ken Griffin. The largest position is worth $4.5M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.